MaxCyte Stock Hits 52-Week Low at $2.62 Amid Market Challenges

Published 03/04/2025, 15:20
MaxCyte Stock Hits 52-Week Low at $2.62 Amid Market Challenges

MaxCyte Inc. (MXCT) stock has touched a 52-week low, falling to $2.62, as the biotechnology company faces a challenging market environment. According to InvestingPro data, the company maintains strong financial health with a current ratio of 10.88, holding more cash than debt on its balance sheet. This latest price level reflects a significant downturn from the previous year, with the stock experiencing a 1-year change of -36.77%. While technical indicators suggest the stock is currently in oversold territory, analysts maintain a bullish stance with price targets ranging from $6 to $9. Investors are closely monitoring MaxCyte’s performance, as the company navigates through the headwinds that have impacted its valuation and investor sentiment. Get deeper insights into MaxCyte’s technical signals and 8 additional exclusive ProTips with InvestingPro. The 52-week low serves as a critical point of reference for both potential buyers looking for an entry point and current shareholders assessing their positions in the context of the company’s long-term prospects. Based on InvestingPro’s Fair Value analysis, the stock currently appears undervalued, despite reporting a gross profit margin of 81.62% in the last twelve months.

In other recent news, MaxCyte Inc. reported a 6% decline in total revenue for 2024, ending the year with $38.6 million. Despite this, the company achieved a 9% increase in core revenue, reaching $32.5 million, driven by a significant 36% growth in Processing Assembly revenue. Analysts from Stifel and BTIG have both adjusted their price targets for MaxCyte, with Stifel lowering its target to $9 and BTIG to $6, though both maintain a Buy rating. BTIG highlighted MaxCyte’s record achievement of six strategic platform license agreements in 2024, ending the year with 28 active agreements. The company has projected core revenue growth of 8-15% for 2025, which includes contributions from the recent SeQure Dx acquisition. MaxSight, a separate entity, reported a 45% decline in Q4 2024 revenue compared to the previous year, though it beat earnings per share expectations. MaxSight also ended the year with a robust cash position of $190.3 million and no debt, projecting an 8-15% growth in core revenue for 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.